AI Engines For more Details: Perplexity Kagi Labs You
Appetite Suppression: Sibutramine works by inhibiting the reuptake of certain neurotransmitters in the brain, including serotonin, dopamine, and norepinephrine. By increasing the levels of these neurotransmitters, sibutramine promotes feelings of fullness and reduces appetite, which can lead to decreased food intake and calorie consumption.
Weight Loss: Sibutramine is used as an adjunct to a reduced-calorie diet and increased physical activity for the management of obesity. Studies have shown that treatment with sibutramine can result in modest weight loss over the short term (e.g., 6-12 months) compared to placebo.
Metabolic Effects: In addition to promoting weight loss, sibutramine may have beneficial effects on certain metabolic parameters, such as improving insulin sensitivity and reducing levels of triglycerides and low-density lipoprotein (LDL) cholesterol. These effects may be particularly relevant for individuals with obesity-related metabolic conditions such as type 2 diabetes and dyslipidemia.
Cardiovascular Risks: Despite its weight-loss benefits, sibutramine has been associated with an increased risk of cardiovascular events, including heart attack, stroke, and cardiac arrhythmias. Due to these safety concerns, regulatory agencies in several countries have either suspended marketing authorizations or withdrawn sibutramine from the market altogether.
Hypertension: Sibutramine can cause increases in blood pressure and heart rate, which may pose risks for individuals with hypertension or cardiovascular disease. Monitoring of blood pressure and heart rate is recommended during treatment with sibutramine, and the medication should be discontinued if significant increases in blood pressure occur.
Psychiatric Effects: Sibutramine may also have psychiatric side effects, including insomnia, anxiety, depression, and mood swings. Individuals with a history of psychiatric disorders should be closely monitored for changes in mood or behavior while taking sibutramine.
Contraindications: Sibutramine is contraindicated in individuals with a history of coronary artery disease, congestive heart failure, arrhythmias, stroke, or uncontrolled hypertension. It should also be avoided in patients with eating disorders, such as anorexia nervosa or bulimia nervosa, due to the risk of exacerbating these conditions.
Withdrawal from the Market: Due to the increased cardiovascular risks associated with sibutramine use, regulatory agencies in several countries, including the United States and European Union, have taken action to restrict or remove sibutramine-containing products from the market. As a result, sibutramine is no longer available for prescription or over-the-counter use in many countries.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0 | 0 | |
Acne | 0.3 | -0.3 | |
ADHD | 3.5 | 0.3 | 10.67 |
Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
Allergic Rhinitis (Hay Fever) | 0.4 | 1.7 | -3.25 |
Allergies | 3.8 | 1.9 | 1 |
Allergy to milk products | 0.6 | 0.4 | 0.5 |
Alopecia (Hair Loss) | 1.2 | 1.2 | |
Alzheimer's disease | 2.2 | 4.2 | -0.91 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.8 | 0.8 | 2.5 |
Ankylosing spondylitis | 2 | 1.1 | 0.82 |
Anorexia Nervosa | 2 | -2 | |
Antiphospholipid syndrome (APS) | 0.8 | 0 | 0 |
Asthma | 0.6 | 1 | -0.67 |
Atherosclerosis | 1.1 | 1 | 0.1 |
Atrial fibrillation | 3.2 | 0.6 | 4.33 |
Autism | 5.3 | 7.5 | -0.42 |
Barrett esophagus cancer | 0.4 | 0 | 0 |
benign prostatic hyperplasia | 0 | 0 | |
Bipolar Disorder | 0.7 | 1.1 | -0.57 |
Brain Trauma | 0.7 | 0.3 | 1.33 |
Carcinoma | 2.6 | 2.4 | 0.08 |
Celiac Disease | 1.5 | 3.7 | -1.47 |
Cerebral Palsy | 1 | 1.1 | -0.1 |
Chronic Fatigue Syndrome | 3 | 4.6 | -0.53 |
Chronic Kidney Disease | 0.5 | 2 | -3 |
Chronic Lyme | 0.3 | -0.3 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.5 | 0.7 | -0.4 |
Chronic Urticaria (Hives) | 0.5 | 0.6 | -0.2 |
Coagulation / Micro clot triggering bacteria | 0.1 | 0.9 | -8 |
Colorectal Cancer | 1.5 | 1.2 | 0.25 |
Constipation | 1.2 | 0.5 | 1.4 |
Coronary artery disease | 1.3 | 1 | 0.3 |
COVID-19 | 7.6 | 11.5 | -0.51 |
Crohn's Disease | 3.7 | 5.2 | -0.41 |
cystic fibrosis | 0 | 0.7 | 0 |
deep vein thrombosis | 0 | 0.5 | 0 |
Depression | 5.4 | 6.2 | -0.15 |
Dermatomyositis | 0 | 0.3 | 0 |
Eczema | 0.5 | 0.5 | 0 |
Endometriosis | 1.6 | 1.4 | 0.14 |
Eosinophilic Esophagitis | 0.4 | -0.4 | |
Epilepsy | 1.8 | 1.6 | 0.13 |
Fibromyalgia | 0.9 | 0.9 | 0 |
Functional constipation / chronic idiopathic constipation | 3.6 | 1.7 | 1.12 |
gallstone disease (gsd) | 1.6 | 0.5 | 2.2 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.1 | 0.8 | 0.38 |
Generalized anxiety disorder | 0.5 | 1.4 | -1.8 |
giant cell arteritis | 0 | 0 | |
Glioblastoma | 0 | 0 | |
Gout | 0.2 | -0.2 | |
Graves' disease | 1 | 1.3 | -0.3 |
Halitosis | 0.6 | 0 | 0 |
Hashimoto's thyroiditis | 1.8 | 0.6 | 2 |
Hidradenitis Suppurativa | 0.1 | 0.4 | -3 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 2.9 | 0.9 | 2.22 |
hypercholesterolemia (High Cholesterol) | 0.2 | 0.4 | -1 |
hyperglycemia | 0 | 1.6 | 0 |
Hyperlipidemia (High Blood Fats) | 0.9 | 0.4 | 1.25 |
hypersomnia | 0.4 | -0.4 | |
hypertension (High Blood Pressure | 1.6 | 3 | -0.88 |
Hypothyroidism | 1 | -1 | |
Hypoxia | 0.5 | 0.5 | |
IgA nephropathy (IgAN) | 2.4 | -2.4 | |
Inflammatory Bowel Disease | 1.4 | 6.6 | -3.71 |
Insomnia | 0.7 | 0.8 | -0.14 |
Intelligence | 0.2 | 0.2 | |
Intracranial aneurysms | 1 | 0.4 | 1.5 |
Irritable Bowel Syndrome | 3.1 | 3.1 | 0 |
Liver Cirrhosis | 2.9 | 2.3 | 0.26 |
Long COVID | 5.9 | 8.6 | -0.46 |
Low bone mineral density | 0.7 | -0.7 | |
Lung Cancer | 0.7 | 1.6 | -1.29 |
ME/CFS with IBS | 0.5 | 2.5 | -4 |
ME/CFS without IBS | 0.6 | 1.8 | -2 |
Menopause | 2 | 2 | |
Metabolic Syndrome | 4.7 | 5.3 | -0.13 |
Mood Disorders | 7.6 | 6.3 | 0.21 |
multiple chemical sensitivity [MCS] | 0.6 | 0.4 | 0.5 |
Multiple Sclerosis | 3.2 | 2.7 | 0.19 |
Multiple system atrophy (MSA) | 0.7 | 1.1 | -0.57 |
Neuropathy (all types) | 0.6 | 0 | 0 |
neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.2 | 5.7 | -3.75 |
NonCeliac Gluten Sensitivity | 0.3 | -0.3 | |
Obesity | 5.6 | 3.2 | 0.75 |
obsessive-compulsive disorder | 4.5 | 2.9 | 0.55 |
Osteoarthritis | 0.4 | 0.4 | 0 |
Osteoporosis | 1.1 | 1.1 | 0 |
pancreatic cancer | 0.3 | 0.3 | |
Parkinson's Disease | 1.7 | 2.7 | -0.59 |
Polycystic ovary syndrome | 1.6 | 1.6 | 0 |
Postural orthostatic tachycardia syndrome | 0 | 0.5 | 0 |
Premenstrual dysphoric disorder | 1.1 | 1.1 | |
primary biliary cholangitis | 0.4 | 0.4 | 0 |
Psoriasis | 3.5 | 0.9 | 2.89 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.1 | 2.4 | 0.71 |
Rosacea | 0.8 | 0.1 | 7 |
Schizophrenia | 4.9 | 1.4 | 2.5 |
scoliosis | 0.2 | 1.2 | -5 |
Sjögren syndrome | 1.9 | 2.6 | -0.37 |
Sleep Apnea | 1.3 | 1 | 0.3 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.1 | 0.6 | -5 |
Stress / posttraumatic stress disorder | 1.3 | 1.9 | -0.46 |
Systemic Lupus Erythematosus | 1.9 | 1.9 | 0 |
Tic Disorder | 1.2 | 1.1 | 0.09 |
Tourette syndrome | 0.2 | 0.2 | 0 |
Type 1 Diabetes | 2.9 | 1.9 | 0.53 |
Type 2 Diabetes | 5.3 | 4.2 | 0.26 |
Ulcerative colitis | 1.5 | 2.9 | -0.93 |
Unhealthy Ageing | 2.9 | 2 | 0.45 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.